RxDoctor Payments Data

Caroline Johns, MD

Endocrinology, Diabetes & Metabolism · Fort Myers, FLNPI 1730543174

Payments from drug & device makers

$950in general payments, 2019–2025

Across 42 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$179
  • Tandem Diabetes Care, Inc.$129
  • Dexcom, Inc.$97
  • Lilly USA, LLC$93
  • Medtronic$88
  • Novo Nordisk$80
  • plus $284 from 8 others

What the payments were for

  • Food & beverage$950100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$950 in reported general payments places this provider in the 25th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$16,885
Medicare patients
213
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide193$317,192
JardianceEmpagliflozin160$253,821
TrulicityDulaglutide117$194,554
MounjaroTirzepatide156$191,959
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/750$75,581
ProliaDenosumab38$64,741
Tresiba Flextouch U-100Insulin Degludec70$58,781
ForteoTeriparatide13$57,165
JanuviaSitagliptin Phosphate35$52,226
Tresiba Flextouch U-200Insulin Degludec38$42,963
FarxigaDapagliflozin Propanediol34$39,865
Lantus SolostarInsulin Glargine,hum.Rec.Anlog218$38,376
Humalog Kwikpen U-100Insulin Lispro94$37,286
Evenity (2 Syringes)Romosozumab-Aqqg16$27,975
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$18,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog, Insulin Lispro$93$454,783332 claims
Novo NordiskOzempic, Novolog$80$326,094213 claims
Sanofi-aventis U.S. LLCLantus$28$3,06115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →